Compare Novavax Inc (NVAX) vs Tapestry, Inc. (TPR) Price & Performance

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.

The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.

TPR trades at $113.39, down 2.86% today, with a bearish technical signal and neutral oscillators. The stock shows strong profitability with a 19.09% net income margin and 197.14% ROE, but net income fell sharply in 2025. Recent earnings beats and a $0.46 dividend highlight operational strength, while cash flow volatility and high debt-to-asset ratios pose concerns. Analyst consensus is strongly bullish with a $174.64 price target.

Outlook remains positive driven by international growth and margin expansion targets, but risks include execution challenges at Kate Spade, tariff pressures, and volatile cash flows. The stock offers value with a reasonable P/E of 15.6, though current price weakness near support at $113 may present a buying opportunity for long-term investors.